相关实验视频

Updated: Sep 17, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

LncRNA MALAT1作为子宫内膜癌的预后生物标志物:一个分子遗传学方法

Xinlian Liu¹, JinBao Xiao¹, Junqi Ma²

¹Department of Gynecological Oncology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, Xinjiang, People's Republic of China.

Discover oncology

|July 1, 2025

概括

转移相关的肺腺癌转录1 (MALAT1) 在子宫内膜癌中升级,与预后不佳相关,并推动瘤生长. 沉默MALAT1可以抑制癌症的进展,并提供一种潜在的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物标志物研究生物标志物研究

背景情况:

子宫内膜癌是一种常见的妇科恶性瘤,预后不同.
识别新的生物标志物和治疗点对于改善患者的治疗结果至关重要.
长非编码RNAs (lncRNAs) 越来越多地被认为是它们在癌症发展中的作用.

研究的目的:

调查转移相关的肺腺癌转录1 (MALAT1) 在子宫内膜癌中的作用.
评估MALAT1作为预后生物标志物和治疗点.

主要方法:

定量实时PCR (RT-qPCR) 用于MALAT1表达分析.
卡普兰-梅尔生存分析以评估预后意义.
在MALAT1倒退后进行体外功能测试 (细胞增殖,细胞亡,血管生成).
涉及竞争内源性RNA (ceRNA) 网络分析的机制研究.
在体内异种移植的小鼠模型来评估MALAT1沉默的治疗疗效.

主要成果:

MALAT1在子宫内膜癌组织中显著上调,与晚期和淋巴血管入侵相关.
高MALAT1表达与较短的整体存活率和无进展的存活率有关.
在试验室中,MALAT1倒置减少了细胞增殖,增加了细胞亡,并损害了血管生成.
MALAT1 作为一个 ceRNA 起作用,将抑制瘤的微RNA (例如,miR-200c,miR-145) 和调节致癌途径.
MALAT1表达与VEGFA和ZEB1.1正相关.
在体内对MALAT1的治疗性沉默减少了瘤生长和微血管密度.

结论:

马拉特1是子宫内膜癌的重要致癌因子.
马拉特1作为一个有前途的预后生物标志物用于子宫内膜癌.
向MALAT1为子宫内膜癌治疗提供了一个潜在的治疗策略.

关键词:

血管新生的产生.细胞亡 (apoptosis) 是一种死亡的过程.竞争的内源性RNA具有竞争性.这是子宫内膜癌的癌症.马拉特语马拉特语马拉特语预测预后预测预测瘤的生长瘤的生长微RNAs 是一个微型RNA.

更多相关视频

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

Published on: April 10, 2018

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Non-LTR Retrotransposons

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...